As immunotherapies have seen rising success in treating several other cancers, researchers are hard at work uncovering why immunotherapy for ovarian cancer has, so far, proven ineffective. In a study … Continued
Dr. Melica Brodeur, of Memorial Sloan Kettering Cancer Center, is a 2022 recipient of OCRA’s Mentored Investigator Grant. With her project, “Exploiting SMARCA4 Alterations for New Therapeutics in Ovarian Cancer,” … Continued
“We are truly in the Golden Age, the Renaissance, if you will, of care for people with ovarian cancer. So much is happening.” Dr. Stephanie Blank Though there is still … Continued
There are many different celebrations involving light during these dark winter days. And certainly, our community is a great source of brightness — from the hope of scientific breakthroughs on … Continued
Dr. Amrita Salvi, of University of Illinois at Chicago, is a 2022 recipient of OCRA’s Mentored Investigator Grant. With her project, “Investigating the Mechanism of Action of PHY34 in HGSOC,” … Continued
Dr. Zelei Yang, of Dana Farber Cancer Institute, is a 2022 recipient of OCRA’s Mentored Investigator Grant. With her project, “Re-engaging the Anti-tumor Immune Response Against Ovarian Cancer,” Dr. Yang … Continued
Dr. Gamze Bildik Elcik, postdoctoral fellow in the Department of Experimental Therapeutics at MD Anderson Cancer Center, is a 2022 recipient of OCRA’s Mentored Investigator Grant. With her project, “DIRAS3 … Continued
Recent research published in JNCCN–Journal of the National Comprehensive Cancer Network has shown that there are clear disparities when it comes to which ovarian cancer patients are receiving treatment in accordance with … Continued
Dr. Erin Wesley, of University of Minnesota Twin Cities, is a 2022 recipient of OCRA’s Mentored Investigator Grant. With her project, “Impact of Cytomegalovirus and Inflammation on NK Cells in … Continued
NCCN guidelines for the management of ovarian cancer, as well as fallopian and primary peritoneal cancers, specify that patients diagnosed with those diseases should have germline and somatic testing. But … Continued
In exciting treatment news, the Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine-gynx (trade name Elahere, made by Immunogen, Inc.), for adults with folate receptor alpha … Continued
Many ovarian cancer patients and survivors wonder what the ideal diet for ovarian cancer may be. In a nutshell – there is no simple answer. In this article, adapted from … Continued
Get email updates about research news, action alerts, and ways to join the fight.
